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Abstract
Respiratory chain dysfunction has been identified in several neurodegenerative disorders. In Friedreich’s ataxia (FA) and
Huntington’s disease (HD), where the respective mutations are in nuclear genes encoding non-respiratory chain
mitochondrial proteins, the defects in oxidative phosphorylation are clearly secondary. In Parkinson’s disease (PD) the
situation is less clear, with some evidence for a primary role of mitochondrial DNA in at least a proportion of patients. The
pattern of the respiratory chain defect may provide some clue to its cause; in PD there appears to be a selective complex I
deficiency; in HD and FA the deficiencies are most severe in complex II/III with a less severe defect in complex IV. Aconitase
activity in HD and FA is severely decreased in brain and muscle, respectively, but appears to be normal in PD brain. Free
radical generation is thought to be of importance in both HD and FA, via excitotoxicity in HD and abnormal iron handling
in FA. The oxidative damage observed in PD may be secondary to the mitochondrial defect. Whatever the cause(s) and
sequence of events, respiratory chain deficiencies appear to play an important role in the pathogenesis of neurodegeneration.
The mitochondrial abnormalities induced may converge on the function of the mitochondrion in apoptosis. This mode of cell
death is thought to play an important role in neurodegenerative diseases and it is tempting to speculate that the observed
mitochondrial defects in PD, HD and FA result directly in apoptotic cell death, or in the lowering of a cell’s threshold to
undergo apoptosis. Clarifying the role of mitochondria in pathogenesis may provide opportunities for the development of
treatments designed to reverse or prevent neurodegeneration. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mitochondrial respiratory chain dysfunction has
now been identi¢ed in a number of neurodegenera-
tive disorders. In some, e.g. Parkinson’s disease
(PD), this may play a role in aetiology and patho-
genesis. In others, the mitochondrial de¢ciency is
known to be secondary to a mutation in a non-res-
piratory chain protein coding gene, e.g. Huntington’s
disease (HD), Friedreich’s ataxia (FA), hereditary
spastic paraplegia (HSP). The apparent predilection
of respiratory chain or oxidative phosphorylation
(OXPHOS) defects for the central nervous system
may be explained by this tissue’s particular depend-
ence on aerobic metabolism. Mitochondrial involve-
ment in Alzheimer’s disease and FA has been se-
lected for special sections in this issue. This review
will focus on respiratory chain involvement in PD,
HD and the recently discovered mitochondrial in-
volvement in HSP.
2. Parkinson’s disease
The clinical characteristics of PD are bradykinesia,
rigidity and tremor. Onset is typically in the sixth or
seventh decade of life, with a lifetime risk of devel-
oping PD of 1 in 40. The main clinical features of
PD are the result of degeneration of dopaminergic
neurones in the substantia nigra pars compacta.
Although other areas may be involved, e.g. locus
ceruleus, substantia innominata, as well as other neu-
rotransmitter systems, e.g. cholinergic, it is the dopa-
mine system on which most attention has been fo-
cused in terms of aetiology, pathogenesis and
treatment. Surviving dopaminergic neurons in the
substantia nigra may contain intracytoplasmic inclu-
sions (Lewy bodies). How these inclusions develop is
not known but they are found elsewhere in the PD
brain as well as in other neurodegenerative diseases
including di¡use Lewy body disease and motor neu-
ron disease (amyotrophic lateral sclerosis).
There is increasing evidence for a signi¢cant genet-
ic component to PD. Early twin studies found no
increase in concordance amongst monozygotic twins,
suggesting little if any genetic in£uence [1^4]. How-
ever, such studies were complicated by several con-
founding factors including ascertainment and sub-
clinical PD in the non-a¡ected twin. The most
recent and reliable studies are those that include
positron emission tomography (PET) assessment
with 18£uoro-dopa [5]. 18Fluoro-dopa PET has the
sensitivity to detect decreased dopamine uptake in
the striatum that re£ects loss of nigrostriatal dopa-
minergic neurons in patients prior to the develop-
ment of the clinical features of PD [6]. This technique
improves the analysis of concordance rates amongst
monozygotic and dizygotic twins and now con¢rms
that a genetic component is likely to contribute to
PD [5].
Several pedigrees with familial parkinsonism have
been described. Inheritance patterns in these families
have usually been autosomal dominant [7^10],
although maternal inheritance has also been de-
scribed [11], implying involvement of mitochondrial
DNA (mtDNA). An important advance in our
understanding of PD came with the identi¢cation
of mutations in the K-synuclein gene in certain auto-
somal dominant parkinsonian families [12^14]. Mu-
tations in this gene have not been identi¢ed in spo-
radic patients with PD, nor in other familial cases
[15]. Nevertheless, the mechanisms by which the mu-
tation in K-synuclein can result in apparently selec-
tive dopaminergic cell death will provide valuable
insights into the events that may result in nigral
cell loss in sporadic, primary PD. Other chromoso-
mal loci have also recently been identi¢ed in certain
PD families [16,17], but the gene products and their
function remain uncharacterised at present.
Mitochondrial involvement in PD was established
with the identi¢cation of complex I de¢ciency in the
substantia nigra [18^20]. The complex I defect ap-
pears to be selective in terms of the involvement of
other components of the OXPHOS system. Analysis
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of other areas of the PD brain, including striatum
(caudate and putamen), cortex, cerebellum, globus
pallidum, tegmentum and substantia innominata,
has not identi¢ed an OXPHOS de¢ciency [21^24].
There is no apparent respiratory chain defect in sub-
stantia nigra or other brain areas in multiple system
atrophy [25], a disorder resembling PD treated with
L-dopa and with severe nigral dopaminergic cell loss.
This suggests that the complex I de¢ciency in PD is
neither related simply to neuronal degeneration nor
to L-dopa toxicity.
At the time of death, the PD substantia nigra has
lost probably s 85% of its dopaminergic neurons,
these neurons comprising 6 5% of the total cell pop-
ulation. Thus a V35% de¢ciency of complex I in
nigral homogenates must re£ect decreased activity
in both neurons and glia. Although complex I immu-
noreactivity is reduced in PD nigral neurons [26] it is
not known whether or not the neurons have a more
severe defect than glia. However, their greater de-
pendence on aerobic metabolism would suggest that
they will be more vulnerable to such a mitochondrial
abnormality. Further studies are needed in this area
to de¢ne in greater detail the extent and e¡ect of the
complex I de¢ciency on dopaminergic neurons.
Lewy bodies are present in high numbers in the
cingulate gyrus of di¡use Lewy body (DLB) brains.
Analysis of complex I activities in this area did not
identify any abnormality, suggesting that the com-
plex I de¢ciency is not related to Lewy body expres-
sion [24]. Complex I activity was also normal in cin-
gulate cortex from AD brains, an area with marked
gliosis, implying that gliosis per se is not a cause of
the complex I defect in PD. Interestingly, reduced
glutathione (GSH) levels are decreased in PD sub-
stantia nigra and AD cingulate cortex suggesting that
there is oxidant stress in all these areas, but that this
is not necessarily associated with complex I de¢-
ciency.
Respiratory chain dysfunction has also been
sought in tissues outside the brain in PD patients.
Data on skeletal muscle remain di⁄cult to interpret
[27]. The ¢rst study using 31phosphorus magnetic
resonance spectroscopy of skeletal muscle found no
abnormality of oxidative phosphorylation [28]. The
second, however, did demonstrate defects [29]. Res-
piratory chain function analysis of skeletal muscle
mitochondria by polarography or of homogenates
has provided con£icting results. These studies have
been reviewed but the majority showed no abnormal-
ity, although severe defects were identi¢ed in a small
proportion of patients [30]. Whilst methodological
variations may explain some of the di¡erences, it
may be that the results of mitochondrial function
assays in PD skeletal muscle re£ect the heterogeneity
of the disease itself (see below). In contrast, analysis
of respiratory chain function in platelets from PD
patients has provided more consistent results (see
[30] for review) [31]. There is a clear consensus for
mitochondrial dysfunction in PD platelets; almost all
studies have demonstrated complex I de¢ciency,
some having also found defects of complexes II^IV.
The severity of the complex I defect does vary be-
tween studies (16^55%), but in none was there su⁄-
cient sensitivity to allow complex I activity to be used
as a bio-marker. The consistency over time of a com-
plex I defect in platelets from PD patients has been
demonstrated [31,32]. The presence of a complex I
de¢ciency in platelets but not PD brain areas outside
the substantia nigra may at ¢rst seem a paradox.
However, there are several possible explanations,
both methodological and biochemical. Respiratory
chain function is most sensitively assessed on isolated
mitochondria. This is demonstrated in platelets
where homogenates showed no abnormality [22]
but enriched mitochondrial fractions did [33]. Frozen
post mortem brain tissue does not easily lend itself to
mitochondrial isolation and so data derived from this
tissue have been based on homogenate analysis.
Thus, whilst the most severe defect is readily identi-
¢ed in substantia nigra, it is possible that homoge-
nate analysis is insu⁄ciently sensitive to detect less
severe defects in other areas. The cause of the se-
verity of the defect in substantia nigra may be multi-
factorial including exacerbation through oxidative
damage generated via, for example, dopamine auto-
oxidation 9 through direct dopamine inhibition [34],
or perhaps re£ecting the e¡ect of a primary aetiolog-
ical factor, e.g. mtDNA mutation. Alternatively,
platelets have pharmacological features in common
with dopaminergic neurons, e.g. uptake of MPP,
presence of monoamine oxidase, which have led
some to suggest that platelets may be used as a mod-
el for dopaminergic neurons [35]. However, caution
must be used in extrapolating pharmacological or
biochemical abnormalities from platelets to neurons.
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Whatever the cause of the complex I de¢ciency in PD
platelets, its presence may be used as a tool to dissect
out some of the aetiological factors which may be
relevant to this disease.
Each mitochondrion contains 2^10 molecules of
mtDNA. MtDNA encodes 22 transfer RNAs
(tRNA), two ribosomal RNAs and 13 proteins: sev-
en subunits of complex I, cytochrome b of complex
III, COI, COII and COIII of complex IV (cyto-
chrome oxidase) and subunits 6 and 8 of complex
V (ATPase). MtDNA is inherited through the mater-
nal line. In excess of 80 mtDNA mutations have been
associated with human disease [36]. Mutations may
occur in protein coding or RNA genes; they usually
co-exist (probably intramitochondrially) with normal
wild-type molecules. The proportion of mutant mol-
ecules may vary from one tissue to another. The level
of mutant load required to induce a respiratory chain
de¢ciency and cell dysfunction is usually high, but
this may vary depending on the tissue’s dependence
on oxidative phosphorylation.
The presence of complex I de¢ciency in PD clearly
raised the possibility that this defect might be deter-
mined by a mutation in one of the mtDNA complex
I genes. However, most cases of PD are sporadic and
do not appear to follow a maternal pattern of inher-
itance as might be expected from an mtDNA muta-
tion. However, it is now clear that the majority of
patients with ‘mitochondrial myopathy’ and a de-
¢ned mtDNA mutation appear as sporadic cases
[37]. Even 40% of patients with the archetypal ma-
ternally inherited disease, Leber’s hereditary optic
neuropathy, have no family history [38]. Thus a his-
tory of maternal inheritance in a disease is not a sine
qua non for mtDNA involvement. Several studies
have sequenced mtDNA from PD patients but no
consistent mutation has been identi¢ed. Some alter-
ations in sequence have been found in greater fre-
quency in PD patients than controls, but this may
to some extent re£ect di¡erent ethnicity and haplo-
type background [39^45].
The presence of the complex I defect in PD pa-
tients o¡ers an opportunity to determine whether this
is caused by a mtDNA defect. Platelets are derived
from bone marrow megakaryocytes and thus have
respiratory chain complexes with both nuclear and
mtDNA encoded subunits. Platelets circulating in
the blood do not have nuclei. It is possible to gen-
erate cells without mtDNA (b0 cells) by exposure
over several passages to, for instance, ethidium bro-
mide or DDC [46]. Such cells can grow and divide in
medium supplemented with pyruvate and uridine. b0
cells can serve as a recipient of donor mtDNA which,
following fusion of an enucleated cell (or platelet)
containing mitochondria, can be replicated in the
cybrid cells. Following this fusion and growth, the
resulting cybrids will have mtDNA and mtDNA en-
coded respiratory chain subunits from the donor,
and nuclear DNA encoded subunits from the host
b0 cells (see Fig. 1). In this model, if a defect of
respiratory chain function is present in the donor
mitochondria and perpetuated in the cybrids follow-
ing fusion, then it must be caused by an abnormality
of the donor mtDNA, as this is the only component
Fig. 1. Schematic illustration of the principle of the b0 cybrid
studies used in the identi¢cation of an mtDNA contribution to
the complex I defect in PD.
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remaining from the donor cells in the cybrids. We
have applied this model to investigate the origin of
the complex I de¢ciency in PD platelets [32].
We hypothesised that those PD patients with the
lowest platelet complex I activity would be those
most likely to bear any putative mtDNA mutation.
Platelets from a preselected group of patients with
the lowest complex I activities were fused with
A549 b0 cells and then grown as mixed or clonal
cybrids. Respiratory chain function analysis in the
mixed cybrids from controls and PD patients identi-
¢ed a signi¢cant complex I de¢ciency in the latter
(25%; P = 0.007). The maintenance of the complex
I defect from platelets to cybrids must therefore be
the result of a defect in the host PD mtDNA. Inter-
estingly, the individual donor platelet complex I ac-
tivity correlated with the complex I activity in the
cybrid cells with that donor’s mtDNA (r = 0.86,
P6 0.001). This correlation allowed the PD and con-
trol populations to be more clearly separated (Fig.
2).
Further studies were then undertaken on one of
the PD patients to determine whether the mtDNA
defect was heteroplasmic. In studies with the
A3243G tRNALeuUUR mutation of mtDNA associ-
ated with encephalomyopathy, we found that the
heteroplasmic mutation segregated randomly in the
A3243G nuclear background to produce a range of
clonal lines with varying mutant load (Gu et al., un-
published observations). Mutant load correlated with
biochemical defects in complexes I and IV in that
v90% mutation was required before de¢ciencies ap-
peared. This was also apparent on staining for cyto-
chrome oxidase cytochemically or immunocyto-
chemically where there was heterogeneity between
the individual cells re£ecting di¡erent mutant loads
between them. Similar clonal studies on the PD pa-
tient’s cybrids produced identical results. Biochemi-
cally, there was a 25% de¢ciency of complex I
(P = 0.005) and 20% de¢ciency of complex IV
(P = 0.005). Staining the clones for cytochrome oxi-
dase activity and with a monoclonal antibody to the
COI mtDNA encoded subunit likewise demonstrated
heterogeneity between cells of the same clone. These
results are identical to those obtained with the
A3243G mtDNA mutation and suggest that the
mtDNA defect in the PD patients may also be het-
eroplasmic.
In summary, these results suggest that in PD pa-
tients preselected by their low complex I activity, a
mtDNA defect caused the mitochondrial de¢ciency,
and that the mtDNA defect may be heteroplasmic.
Swerdlow et al. [47] used the b0 model in PD and
have also found a complex I defect in mixed cybrids
but from a group of unselected patients. The b0 mod-
el results do not indicate whether the PD associated
mtDNA defect is inherited or somatic. It is possible,
for instance, that somatic mtDNA mutations may
have arisen in the patient’s bone marrow or blood
from some toxic in£uence (genetic or environmental).
These mutations, likely to be multiple if secondarily
generated, would produce the platelet complex I de-
¢ciency and be perpetuated in culture to cause the
defect in mixed and clonal cybrids. The distinction
between inherited and somatic mutations in this in-
stance may be determined either by the identi¢cation
of a particular signi¢cant mtDNA base change and
Fig. 2. Relationship between the complex I/CS ratios in the
control (a) and PD patient (R) platelet mitochondrial fractions
and their respective Cxl/CS ratio in the platelet A549 b0 mixed
cybrid lines. The patient studied further by clonal cybrid analy-
sis is indicated (F). The mean þ S.D. for the control and PD
group are indicated. Spearman correlation: r = 0.86, P6 0.001
(see ref. [32]).
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following its maternal lineage, or using PD nuclear
backgrounds in the b0 model to see if they induce
secondary mtDNA changes.
The heterogeneity in expression of cytochrome ox-
idase activity and subunits was paralleled by changes
in mitochondrial membrane potential (v8m) as
measured by JC-1. Whilst some of the clones with
the PD mtDNA had apparently normal v8m, other
cells had low v8m. To some extent this is an indirect
measure of OXPHOS and re£ects the biochemical
defects outlined above. Nevertheless, the demonstra-
tion that the PD mtDNA defect can induce a fall in
the v8m has important implications for its role in
lowering the apoptotic threshold of cells.
2.1. Environmental factors
MPTP was identi¢ed as the contaminant of a me-
peridine analogue ‘designer drug’ responsible for in-
ducing parkinsonism in a small group of drug ad-
dicts in California.
MPTP appears to induce clinical features similar
to, but not identical with, idiopathic PD, but which
still remain responsive to dopamine receptor activa-
tion. Pathological study of a brain from an MPTP
addict with parkinsonism showed severe destruction
of dopaminergic neurons in the substantia nigra [48].
18Fluoro-dopa positron emission tomography in pa-
tients with MPTP parkinsonism indicated progres-
sion of nigrostriatal cell loss over seven years at a
rate faster than aging and comparable with idio-
pathic PD [49]. This implies that the toxicity of this
compound continues long after initial exposure and
indicates the presence of ongoing biochemical abnor-
malities causing cell death. MPTP is a protoxin, me-
tabolised to its active derivative 1-methyl-4-phenyl-
pyridinium (MPP) by monoamine oxidase B
(MAO-B), the distribution of which therefore deter-
mines the site of toxicity. MPP is a speci¢c rever-
sible inhibitor of complex I and results in a fall in
ATP levels. MPP probably interacts with complex I
at the same site as rotenone and piericidin A [50].
MPP induces more severe and irreversible inhibi-
tion of complex I if cytochrome oxidase (complex
IV) is inhibited [51]. This inhibition was prevented
with free radical scavengers indicating oxidative
damage of complex I under these conditions. Com-
plex I inhibition results in increased free radical gen-
eration from the respiratory chain and so the MPP
model suggests that a self amplifying cycle of com-
plex I de¢ciency and damage may result in progres-
sive cell damage. Such a situation would ¢t well with
the progressive striatal lesion in MPP exposed pa-
tients as determined by 18£uoro-dopa PET. There is
increasing evidence that MPP generates free radi-
cals and oxidative damage in addition to causing
complex I inhibition [52,53]. For instance, the nitric
oxide synthase inhibitor 7-nitroindazole has been
shown to protect monkeys [54] and rodents [55].
However, there is also evidence that 7-nitroindazole
also inhibits MAO-B, and this would prevent con-
version of MPTP to MPP [56].
1,2,3,4-Tetrahydroisoquinoline (TIQ) and 2-meth-
yl-TIQ are both structurally related to MPTP and
both have been found in human brain, including a
patient with PD in whom the level of TIQ was great-
er than controls [57,58]. TIQ can be toxic to dopa-
minergic neurons and induce motor de¢cits in mon-
keys. Interestingly, TIQ is also a complex I inhibitor
[59]. N-Methyl TIQ is a methylation product of TIQ
and is a substrate for MAO-B, producing n-methyl-
isoquinolinium (NMIQ). NMIQ inhibits tyrosine
hydroxylase and MAO. It is found in certain food-
stu¡s and can cross the blood brain barrier, but can
also be formed by condensation reaction in the brain.
3. Huntington’s disease
HD is a neurodegenerative disorder characterised
by ataxia, chorea and dementia. Onset is usually in
adulthood, although a juvenile form is recognised.
HD is an autosomal dominant disease now known
to be caused by an abnormal CAG expansion within
the IT15 gene on chromosome 4. This gene encodes
huntingtin, a widely expressed 349-kDa protein of
unknown function. Cell culture models expressing
mutant huntingtin develop intraneuronal inclusions
[60] of a similar type to those seen in brains from
HD patients [61^64].
As with PD, the pathology of HD focuses primar-
ily on a select neuronal population ^ the Q-amino-
butyric acid containing spiny neurons of the caudate
nucleus, in the case of HD. Other areas such as the
putamen and cerebral cortex are less a¡ected, and
the cerebellum is relatively spared. An important
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clue to the pathogenesis of mutant huntingtin expres-
sion will be an understanding of how this widely ex-
pressed protein can result in such speci¢c neuronal
damage when present in mutant form.
Excitotoxicity has been suggested as playing an
important role in HD. This is dependent upon glu-
tamate excitation of N-methyl-D-aspartate (NMDA)
receptors, inward £ow of calcium, activation of nitric
oxide synthase and production of nitric oxide (NOc)
[65]. NOc and particularly peroxynitrate (ONOO3),
the product of its reaction with superoxide (Oc32 ) are
damaging radical species. A critical factor in this
pathway is a defect in energy metabolism which re-
leases the magnesium blockade of NMDA receptor
activation and renders ambient levels of glutamate
toxic. There is now both in vivo and post mortem
evidence for a defect of energy metabolism in HD.
Striatal and cerebral cortex glucose metabolism is
decreased in HD and appears to precede bulk tissue
loss [66,67]. Elevated lactate levels in occipital cortex
have been identi¢ed [68] and recently the length of
CAG repeat has been found to correlate with lactate
levels in HD striatum [68]. Another study of lactate
levels by magnetic resonance spectroscopy, however,
did not ¢nd any di¡erence between HD and controls
[69]. Direct measurement of respiratory chain activity
in HD caudate demonstrated a severe de¢ciency in
the activities of complexes II and III (56%,
P6 0.0005) and a 33% (P6 0.01) de¢ciency of com-
plex IV [70]. A similar but less severe pattern of
de¢ciency was also seen in HD putamen, but not
cerebral cortex or cerebellum [71,72]. A 92% de¢-
ciency of aconitase activity has also been found in
HD caudate, with a 73% defect in putamen, 48% in
cerebral cortex but normal levels in cerebellum. In-
terestingly this distribution of aconitase de¢ciency
mimics more closely the pathology of HD. Aconitase
is an iron-sulphur (FeS) containing enzyme which
participates in the tricarboxylic acid cycle and in
iron homeostasis. Aconitase activity is particularly
susceptible to inhibition by Oc32 , and also by NO
c/
ONOO3 [73^75]. Complexes II and III are FeS con-
taining enzymes and are also sensitive to inhibition
by NOc [72]. The pattern of enzyme loss in HD brain
therefore supports the involvement of NOc and ex-
citotoxicity in pathogenesis.
Respiratory chain activities were normal in HD
platelets [70], although another study had found a
complex I de¢ciency [76]. Mutant huntingtin is also
expressed in HD ¢broblasts but respiratory chain
and aconitase activities were not signi¢cantly di¡er-
ent from control [72].
Respiratory chain enzyme activity in three of four
HD patients, in whom muscle biopsies had been per-
formed, showed decreases in complex I activity [77].
Thus, whilst there is consensus on a mitochondrial
de¢ciency in HD striatum. The situation in tissues
outside the brain is less clear. If a mitochondrial
defect were unequivocally demonstrated in a tissue
which lacked the biochemical and pharmacological
properties peculiar to the striatum, then a more di-
rect link between the CAG repeat in the huntingtin
mutation and the mitochondrial defect could be
made [78].
A mouse model of HD has been created with a
transgene containing approximately one kilobase of
the human HD promoter region, exon one, carrying
CAG repeat expansions of 155^156 units, and 262
base pairs of intron one [79]. The mouse line with
141^157 CAG repeats exhibits progressive neurolog-
ical disease from age two months [80]. Neuronal in-
tranuclear inclusions (NII) in the mouse striatum are
also correlated with frequent indentations of the nu-
clear membrane and an increase in nuclear pores,
observations almost identical to those found in HD
brains (see above). The NIIs stain positively for hun-
tingtin and ubiquitin [80]. NIIs appear ¢rst in the
cerebral cortex, precede the onset of neurological
features, and spare the NADPH diaphorase positive
neurons of the striatum. The rate of formation of
NIIs appears largely dependent upon mutant protein
expression levels. These results indicate that the N-
terminal fragment of huntingtin bearing an abnormal
CAG repeat is su⁄cient to induce a neurological
disease in mice which resembles HD, and induces
morphological changes (NIIs) identical to those
found in HD and which parallel, but antedate, neu-
ropathological changes.
The mouse model of HD provides an interesting
opportunity to determine the role that mitochondrial
dysfunction might play in HD. It could be predicted,
for instance, that a mitochondrial de¢ciency in the
mouse model brain that was present prior to cell loss
might be part of the cascade of biochemical events
that begins with mutant huntingtin expression and
ends with neuronal cell death. Similarly, the cell cul-
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ture models of mutant huntingtin expression now
being developed should again provide the means to
investigate the role of mitochondrial dysfunction in
HD pathogenesis.
Nevertheless, the pattern of enzyme defects, their
severity and their anatomical distribution support the
role of excitotoxicity in HD. We have suggested pre-
viously that a small increase in NOc generation from
excitotoxicity can lead to reversible complex IV in-
hibition [81]. This in turn would lead to increased
Oc32 generation from the respiratory chain in the
presence of an inhibitor of the chain [51]. The Oc32
thus produced, together with the NOc generated from
excitotoxicity will inactivate aconitase. This pattern
of apparently isolated aconitase inhibition may re-
£ect events in the HD cortex, where excitotoxicity
will be limited in comparison to the striatum. Higher
levels of NOc generation, such as might occur in the
striatum, will result in greater NOc, Oc32 and ONOO
3
production. This will cause inhibition of complex II
and III in particular. These events then lay the foun-
dation for the creation of a self-amplifying cycle of
respiratory chain inhibition and free radical genera-
tion. Oxidative damage to protein, lipids and DNA
together with impaired synthesis resulting from this
cycle will reduce cell viability and could induce cell
death by apoptosis or necrosis [82]. These events are
summarised in Fig. 3.
4. Hereditary spastic paraplegia
Hereditary spastic paraplegia (HSP) has a preva-
lence of approximately 1 in 10 000. Autosomal dom-
inant, autosomal recessive and X-linked forms of
HSP have been described [83]. Three loci on chro-
mosomes 14q, 2p and 15q have been associated with
an autosomal dominant form [84^86], whilst a locus
on 8q is found in recessive families [87]. Patients with
HSP may present from childhood to adulthood with
gradual onset and progression of leg sti¡ness and
weakness. Additional features such as a neuropathy,
ataxia, retinitis, optic atrophy and deafness may be
identi¢ed in some patients.
To date, the genes responsible for HSP were only
known in X-linked forms where mutations in the
L1CAM and PLP genes on Xq28 and Xq22, respec-
tively, were described [88,89]. However, a new gene
defect has recently been found in pure HSP families
with autosomal recessive inheritance linked to a lo-
cus on 16q24.3 [90]. The gene product has been
termed paraplegin and has 795 amino acids [91]. Par-
aplegin contains an N-terminus targeting sequence
and has been shown to be imported into mitochon-
dria with a processed molecular mass of 81 kDa.
Di¡erent mutations in the paraplegin gene have
also been identi¢ed in two additional recessive HSP
families supporting the role of the defective protein
in HSP. Muscle biopsies from two severely a¡ected
and two mildly a¡ected patients with paraplegin mu-
tations showed mitochondrial abnormalities. The
more severe cases had ragged red, succinate dehydro-
genase positive ¢bres which stained negatively for
cytochrome oxidase (complex IV); mitochondrial
paracrystalline inclusions were seen in some ¢bres.
These morphological changes are typical of myopa-
thies associated with mitochondrial DNA mutations.
Similar abnormalities were seen in the remaining two
patients, but were present in lower frequency. Future
studies will be required to de¢ne the biochemical
de¢ciency associated with mitochondrial structural
changes and to determine the role of paraplegin in
mitochondrial function.
5. Friedreich’s ataxia
Friedreich’s ataxia (FA) is an adolescent autoso-
mal recessive disorder with a prevalence of approx-
imately 1 in 50 000. The main clinical features include
progressive ataxia, dysarthria, skeletal deformities,
hypore£exia, pyramidal features and a hypertrophic
cardiomyopathy. Most patients are wheelchair-
bound within 10^15 years of onset and die from pro-
gressive cardiac failure. Pathological processes in FA
Fig. 3. Schematic representation of the proposed biochemical
events causing mitochondrial dysfunction in Huntington’s dis-
ease.
BBABIO 44701 29-1-99
A.H.V. Schapira / Biochimica et Biophysica Acta 1410 (1999) 159^170166
primarily a¡ect the central and peripheral nervous
systems and consist of a distal axonopathy of ‘dy-
ing-back’ type a¡ecting the large sensory axons of
the dorsal root ganglia and the spinocerebellar and
pyramidal tracts in the cord, with subsequent loss of
the parent cell bodies.
The molecular genetic defect in 98% of patients
with Friedreich’s ataxia has been identi¢ed as an
unstable GAA triplet repeat in intron 1 of the fra-
taxin (X25) gene [92] resulting in a de¢ciency of fra-
taxin protein presumably by interfering with RNA
processing [93]. RNA analysis has shown frataxin
transcription to be highest in the heart, spinal cord
and dorsal root ganglia which correlates well with
the pattern of degeneration observed in the disease.
The function of frataxin is not known. However,
in yeast, deletion of the frataxin gene homologue,
YFH1, which shares a highly conserved C-terminal
domain with frataxin, resulted in severe growth def-
icit on fermentable carbon sources and an inability to
grow on glycerol and ethanol implying a defective
oxidative phosphorylation system. The connection
with mitochondria was strengthened by the presence
of a predicted N-terminal mitochondrial targeting
sequence [94], and the mitochondrial localisation of
frataxin was con¢rmed using £uorescence micro-
scopy [95,96], and its association with mitochondrial
membranes has recently been con¢rmed [93]. The
role of frataxin in mitochondria is not known, how-
ever, several theories have been proposed. The dam-
age and/or loss of mtDNA in yeast lacking the
YFH1 gene have led to the suggestion that frataxin
may be required for mtDNA replication or mainte-
nance [97], although loss of mtDNA is a relatively
common observation in yeast PET mutants [98^101].
Our own studies suggest that mtDNA levels are also
decreased in FA myocardium (J. Bradley, personal
communication). Increased blood lactate levels in pa-
tients with FA support the hypothesis that oxidative
phosphorylation is impaired [102]. There are con£ict-
ing reports that certain mitochondrial enzyme activ-
ities are decreased in FA cells. These have included
pyruvate dehydrogenase, glutamate dehydrogenase,
K-ketoglutarate dehydrogenase and complex I^III ac-
tivities [103^106]. A recent study of two FA patients
found decreased activity of complexes I^III and aco-
nitase in heart homogenate [107]. Respiratory chain
and aconitase activities were studied in skeletal
muscle, lymphocytes and ¢broblasts from a single
FA patient and were found to be normal. The sim-
ilarity between a de¢ciency of the antioxidant vita-
min E and Friedreich’s ataxia has led to the sugges-
tion that frataxin may be involved in the antioxidant
defence of the cell [93]. The connection with abnor-
mal mitochondrial activities is further strengthened
by the fact that vitamin E de¢ciency in rats results
in markedly decreased complex I and IV activities
[108] although there is no evidence of large scale
mtDNA abnormalities in this model (unpublished
data).
Frataxin has been suggested to be involved in mi-
tochondrial iron metabolism. The evidence for this
comes from the fact that the yeast frataxin homo-
logue, YFH1, has been shown to suppress a mutant
unable to grow on iron limited medium [109]. In
addition, in iron rich medium the high a⁄nity iron
transport system is not usually detectable, but in cells
with a deletion of the YFH1 gene this transport sys-
tem was induced even at high iron concentrations
resulting in increased iron uptake [109]. In this mu-
tant there is an increase in the mitochondrial iron
levels, but this is not a simple re£ection of the in-
creased cellular iron levels which implies frataxin
may be involved in mitochondrial iron metabolism
[109]. As predicted from Fenton chemistry these cells
were very sensitive to H2O2 treatment and therefore
are vulnerable to oxidative stress and damage [109].
Mitochondrial dysfunction caused by deposition of
iron could account for the features of FA. The mi-
tochondrial respiratory chain is a major generator of
cellular free radicals. Oxidative stress and damage
would be exacerbated in the presence of free iron
which, by Fenton chemistry, could generate hydroxyl
ions. The proximity of mtDNA and the mitochon-
drial respiratory chain to the site of free radical gen-
eration may contribute to the abnormalities of
mtDNA and mitochondrial respiratory chain func-
tion that might result. Neurons and cardiac cells
are primarily involved in FA pathology. They are
highly dependent upon oxidative phosphorylation
and consequently would be particularly susceptible
to defects of the respiratory chain. However, it is
not yet apparent why all neurons are not involved.
This could re£ect di¡erential frataxin expression,
with those tissues involved having the highest fratax-
in expression, or it may depend on the length and
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diameter of the axons that the neuronal perikarya
have to support. The neurons initially a¡ected con-
sistently possess long large diameter axons. Failure
of the cell bodies to support these axons could result
in the distal axonopathy that occurs. In humans, the
phenotype observed in the yeast model is unlikely to
be compatible with life. The milder phenotype is
likely to re£ect residual frataxin levels in the patient’s
cells or alternative mechanisms performing the fra-
taxin role. Null mutants for frataxin have not yet
been identi¢ed in humans, possibly because they
may be fatal. However, there is a correlation between
genotype and phenotype with larger GAA repeats
being associated with lower frataxin mRNA and pro-
tein expression and earlier onset and increased se-
verity of the disease [93,110^112].
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